Low endoscopy bleeding risk in patients with congenital bleeding disorders.


Journal

Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 18 04 2018
revised: 06 06 2018
accepted: 17 01 2019
pubmed: 13 2 2019
medline: 30 4 2019
entrez: 13 2 2019
Statut: ppublish

Résumé

Haemophilia A and haemophilia B, von Willebrand disease (VWD), factor VII deficiency and factor XI deficiency are congenital bleeding disorders predisposing to bleeding during invasive procedures. The ageing population of people with congenital bleeding disorders will likely increasingly require gastrointestinal endoscopy. The bleeding risk postgastrointestinal endoscopy and optimal prophylactic treatment regimens are not well described. We performed a retrospective chart review at the McGill University Health Centre. Adult patients with haemophilia A or B, VWD, FVII deficiency and FXI deficiency who underwent gastrointestinal endoscopic procedures were included. Bleeding prophylaxis included combinations of plasma-derived factor (VWD) or recombinant factor (haemophilia A and haemophilia B), desmopressin and/or tranexamic acid. Our primary outcome was the 72-hour postendoscopy bleeding rate. One hundred and four endoscopies were performed in 48 patients. Haemophilia A (45.3% of endoscopies) was the most common bleeding disorder, followed by VWD (38.5%), FXI deficiency (8.7%), haemophilia B (4.8%) and FVII deficiency (2.9%). All patients were reviewed by the Haemophilia Treatment Center with peri-procedure treatment protocols put in place as required. The overall 72-hour bleeding rate was 0.96%, confidence interval (CI) 95% (0.17%-5.25%). The colonoscopic postpolypectomy bleeding rate was 1/21 (4.8%, CI 95% (0.9%-22.7%)) in comparison with the general population rate of 0.3%-10% for high-risk endoscopy (including colonoscopic polypectomy). To the best of our knowledge, this is the largest study describing patients with inherited bleeding disorders undergoing gastrointestinal endoscopy. The bleeding risk is not significantly higher to the general population when haemostatically managed by a team experienced in bleeding disorders.

Identifiants

pubmed: 30748066
doi: 10.1111/hae.13691
doi:

Substances chimiques

Antifibrinolytic Agents 0
Coagulants 0
Tranexamic Acid 6T84R30KC1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

289-295

Informations de copyright

© 2019 John Wiley & Sons Ltd.

Auteurs

Marcel Tomaszewski (M)

Internal Medicine, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.

Marc Bienz (M)

Internal Medicine, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.

Omar Kherad (O)

Internal Medicine, Hôpital de la Tour and University of Geneva, Meyrin, Switzerland.

Sophie Restellini (S)

Service de gastroentérologie et d'hépatologie, Département des spécialités de Médecine, Hôpitaux Universitaires de Genève, Geneva, Switzerland.

Tania Laflèche (T)

Division of Hematology, McGill University Health Centre, Quebec, Canada.

Alan Barkun (A)

Division of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada.

Margaret Warner (M)

Division of Hematology, McGill University Health Centre, Quebec, Canada.

Talat Bessissow (T)

Division of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH